Peer B. Christensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peer B. Christensen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
A.L. Laursen
2 shared publicationsH.B. Krarup
2 shared publicationsJ. Gerstoft
2 shared publicationsL.G. Madsen
2 shared publicationsS. Hallager
2 shared publicationsA. Møller
1 shared publication
Latest Publications
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S287
Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon gives very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C: final results of the 4WIDUC study
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S287
Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon gives very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C: final results of the 4WIDUC study
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S706-S707
Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S706-S707
Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S624-S625
Mortality among Patients with Chronic Hepatitis C and Cirrhosis in Denmark – A Nationwide Danhep Cohort Study
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S624-S625
Mortality among Patients with Chronic Hepatitis C and Cirrhosis in Denmark – A Nationwide Danhep Cohort Study
- 1 February 1999
- Published by Wiley in Transfusion
- Vol. 39 (2) , 188-193
Transfusion-acquired hepatitis C: the Danish lookback experience
In 1996, the Danish National Board of Health recommended hepatitis C virus (HCV) lookback to identify recipients of blood components from donors found to be positive since the implementation of anti-HCV screening in 1991. The aim was to accumulate results of the lookback at a national level and to describe the morbidity of the infected recipients. Records of transfusion were identified for at least 10 years back, and recipients still alive were tested for hepatitis C. Those with positive results were referred for clinical evaluation. A total of 150 anti-HCV-positive Danish donors had donated blood to 1018 transfusion recipients, of whom 288 (29%) were still alive. Because of age, malignancy, or other severe diseases, 118 (41%) of these were not contacted. Of 157 recipients screened for HCV, 128 (82%) were anti-HCV positive on enzyme-linked immunosorbent assay, and 88 (56%) were HCV RNA positive. Among the HCV RNA-positive recipients, symptoms were present in 38 percent (25/66 reported), elevated alanine aminotransferase was found in 53 percent (41/77 tested), and cirrhosis was found in 11 percent (6/54 biopsied). Treatment with interferon alpha was initiated in 23 patients, corresponding to 26 percent of HCV RNA positive recipients. Among tested recipients in the Danish HCV lookback, most were anti-HCV positive and more than half were still viremic. The morbidity was considerable, and one-fourth of viremic recipients entered treatment.
- 1 February 1999
- Published by Wiley in Transfusion
- Vol. 39 (2) , 188-193
Transfusion-acquired hepatitis C: the Danish lookback experience
In 1996, the Danish National Board of Health recommended hepatitis C virus (HCV) lookback to identify recipients of blood components from donors found to be positive since the implementation of anti-HCV screening in 1991. The aim was to accumulate results of the lookback at a national level and to describe the morbidity of the infected recipients. Records of transfusion were identified for at least 10 years back, and recipients still alive were tested for hepatitis C. Those with positive results were referred for clinical evaluation. A total of 150 anti-HCV-positive Danish donors had donated blood to 1018 transfusion recipients, of whom 288 (29%) were still alive. Because of age, malignancy, or other severe diseases, 118 (41%) of these were not contacted. Of 157 recipients screened for HCV, 128 (82%) were anti-HCV positive on enzyme-linked immunosorbent assay, and 88 (56%) were HCV RNA positive. Among the HCV RNA-positive recipients, symptoms were present in 38 percent (25/66 reported), elevated alanine aminotransferase was found in 53 percent (41/77 tested), and cirrhosis was found in 11 percent (6/54 biopsied). Treatment with interferon alpha was initiated in 23 patients, corresponding to 26 percent of HCV RNA positive recipients. Among tested recipients in the Danish HCV lookback, most were anti-HCV positive and more than half were still viremic. The morbidity was considerable, and one-fourth of viremic recipients entered treatment.